$0.46 0.00 (0.02%) Threshold Pharmaceuticals - NASDAQ

Dec. 7, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 0.46
Trade Time: Dec 07 04:00 PM Eastern Daylight Time
Change: +0.00 (0.02%)
Prev Close: 0.46
Open: 0.45
Bid: 0.46
Ask: 0.46
  1. Threshold Pharmaceuticals Announces Workforce Reduction

    GuruFocus | Dec. 18, 2015 | 23:06PM EST
  2. Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not ...

    GuruFocus | Dec. 7, 2015 | 18:46PM EST
  3. Threshold Pharmaceuticals Announces Preclinical Data on Combination of Evofosfamide With Immune Checkpoint Inhibitors to Be Presented at the SITC 2015 Meeting

    Benzinga | Nov. 3, 2015 | 08:15AM EST
  4. Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide

    GuruFocus | Oct. 13, 2015 | 23:02PM EST
  5. Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide

    Benzinga | Oct. 13, 2015 | 06:02AM EST
  6. Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw Annual ...

    GuruFocus | Sep. 3, 2015 | 23:04PM EST
  7. Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) ...

    GuruFocus | Aug. 27, 2015 | 23:03PM EST
  8. Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib ...

    GuruFocus | Aug. 11, 2015 | 23:03PM EST
  9. Threshold Pharma, ATOMIC Initiate First Phase 2 Trial of TH-4000 in Patients with Advanced EGFR-Mutant, T790M-NSCLC

    Benzinga | Aug. 11, 2015 | 06:06AM EST
  10. Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald ...

    GuruFocus | Jul. 1, 2015 | 23:03PM EST
  11. Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL

    GuruFocus | May. 12, 2015 | 15:46PM EST
  12. Threshold Pharma Offers Preclinical Data Suggesting TH-4000 Could Overcome Resistance to Conventional EGFR Tyrosin Kinase Inhibitors

    Benzinga | Apr. 22, 2015 | 07:03AM EST
  13. Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) ...

    GuruFocus | Dec. 6, 2014 | 15:01PM EST
  14. Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in ...

    GuruFocus | Nov. 25, 2014 | 11:03AM EST
  15. Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus ...

    GuruFocus | Nov. 17, 2014 | 11:04AM EST
Trading Center